Skip to content

Insider · CIK 0002101296

Venkatesh Alagirisamy

cooofficer

Files at NKE (NIKE, Inc.). First filing Aug 7, 2026, latest Sep 10, 2026.

In brief

Venkatesh Alagirisamy files SEC Form 4 as COO at NKE (NIKE, Inc.). Since Aug 7, 2026, Venkatesh Alagirisamy has reported 0 open-market buys worth $0 and 2 open-market sells worth $175k, the latest filed on Sep 10, 2026.

A track record needs three past buys with six months of prices behind them; Venkatesh Alagirisamy has 0, so none is measured yet.

The newest scored trade: sold $138k of NKE on Sep 9, 2026, filed Sep 10, 2026, scored 26 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $175k.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $175k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

NKE: NIKE, Inc.

NKEOct 9, 2026 · close 34.71

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
26Weak
NKEsell 310b5-1
NIKE, Inc.
$138k
3,671 shares
-3%0% from low-48% from high
21Weak
NKEsell 510b5-1
NIKE, Inc.
$37k
890 shares
-1%+4% from low-45% from high

Planned sales

Form 144 notices this insider filed before selling restricted or control stock, newest first.

FiledCompanySharesValueSale datePast 3 months
Sep 9, 2026 NKE
NIKE, Inc.
3,671
0.00% of outstanding
$138kSep 9, 2026$37k
Aug 5, 2026 NKE
NIKE, Inc.
890
0.00% of outstanding
$37kAug 5, 2026none

Transactions

Every row this insider has filed, 10 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Sep 9, 2026NKE
NIKE, Inc.
SOpen-market sale
Class B Common Stock10b5-1
-3,671$37.59$138k104,86234 d ago
Sep 1, 2026NKE
NIKE, Inc.
AGrant or award
Class B Common Stock
+37,166$0.00$0111,98641 d ago
Sep 1, 2026NKE
NIKE, Inc.
FTax withholding
Class B Common Stock
-3,453$39.06$135k108,53341 d ago
Sep 1, 2026NKE
NIKE, Inc.
AGrant or award
Non-Qualified Stock Option (Right to Buy)derivative
+135,624$0.00$0135,62441 d ago
Aug 5, 2026NKE
NIKE, Inc.
SOpen-market sale
Class B Common Stock10b5-1
-890$41.60$37k74,820Aug 7, 2026
Aug 3, 2026NKE
NIKE, Inc.
FTax withholding
Class B Common Stock
-837$41.71$35k75,710Aug 5, 2026
Jun 10, 2026NKE
NIKE, Inc.
FTax withholding
Class B Common Stock
-9,853$44.65$440k76,547Jun 12, 2026
Dec 10, 2025NKE
NIKE, Inc.
AGrant or award
Class B Common Stock
+5,429$0.00$054,824Dec 16, 2025
Dec 10, 2025NKE
NIKE, Inc.
AGrant or award
Class B Common Stock
+31,216$0.00$086,040Dec 16, 2025
Dec 10, 2025NKE
NIKE, Inc.
AGrant or award
Non-Qualified Stock Option (Right to Buy)derivative
+17,615$65.79$1.2M17,615Dec 16, 2025

Questions about Venkatesh Alagirisamy

Answered from the filings on this page, as of the latest one.

Is Venkatesh Alagirisamy buying or selling?

In the last 12 months Venkatesh Alagirisamy reported 0 open-market buys worth $0 and 2 open-market sells worth $175k on SEC Form 4; the latest was sold $138k of NKE on Sep 9, 2026. Grants, option exercises and tax withholding are not counted.

How did Venkatesh Alagirisamy's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Venkatesh Alagirisamy has 0.

Where does Venkatesh Alagirisamy file Form 4?

Venkatesh Alagirisamy has filed Form 4 at NKE (NIKE, Inc.) as EVP: CHIEF OPERATING OFFICER. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.